KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Goodwill & Intangibles (2022 - 2025)

Rigel Pharmaceuticals has reported Goodwill & Intangibles over the past 4 years, most recently at $24.7 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 8.68% year-over-year to $24.7 million; the TTM value through Dec 2025 reached $24.7 million, down 8.68%, while the annual FY2025 figure was $24.7 million, 8.68% down from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $24.7 million at Rigel Pharmaceuticals, down from $25.3 million in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $28.9 million in Q1 2024 and troughed at $13.9 million in Q4 2023.
  • A 4-year average of $22.0 million and a median of $25.3 million in 2025 define the central range for Goodwill & Intangibles.
  • Biggest five-year swings in Goodwill & Intangibles: soared 96.6% in 2024 and later dropped 8.68% in 2025.
  • Year by year, Goodwill & Intangibles stood at $15.0 million in 2022, then fell by 7.48% to $13.9 million in 2023, then surged by 95.27% to $27.1 million in 2024, then dropped by 8.68% to $24.7 million in 2025.
  • Business Quant data shows Goodwill & Intangibles for RIGL at $24.7 million in Q4 2025, $25.3 million in Q3 2025, and $25.9 million in Q2 2025.